Cargando…

Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study

BACKGROUND: Rapid diagnostic tests detecting microbial resistance are needed for limiting the duration of inappropriateness of empirical antimicrobial therapy (EAT) in intensive care unit patients, besides reducing the use of broad-spectrum antibiotics. We hypothesized that the betaLACTA® test (BLT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Garnier, Marc, Rozencwajg, Sacha, Pham, Tài, Vimont, Sophie, Blayau, Clarisse, Hafiani, Mehdi, Fulgencio, Jean-Pierre, Bonnet, Francis, Mainardi, Jean-Luc, Arlet, Guillaume, Fartoukh, Muriel, Gallah, Salah, Quesnel, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488410/
https://www.ncbi.nlm.nih.gov/pubmed/28655352
http://dx.doi.org/10.1186/s13054-017-1746-6
_version_ 1783246648119394304
author Garnier, Marc
Rozencwajg, Sacha
Pham, Tài
Vimont, Sophie
Blayau, Clarisse
Hafiani, Mehdi
Fulgencio, Jean-Pierre
Bonnet, Francis
Mainardi, Jean-Luc
Arlet, Guillaume
Fartoukh, Muriel
Gallah, Salah
Quesnel, Christophe
author_facet Garnier, Marc
Rozencwajg, Sacha
Pham, Tài
Vimont, Sophie
Blayau, Clarisse
Hafiani, Mehdi
Fulgencio, Jean-Pierre
Bonnet, Francis
Mainardi, Jean-Luc
Arlet, Guillaume
Fartoukh, Muriel
Gallah, Salah
Quesnel, Christophe
author_sort Garnier, Marc
collection PubMed
description BACKGROUND: Rapid diagnostic tests detecting microbial resistance are needed for limiting the duration of inappropriateness of empirical antimicrobial therapy (EAT) in intensive care unit patients, besides reducing the use of broad-spectrum antibiotics. We hypothesized that the betaLACTA® test (BLT) could lead to early increase in the adequacy of antimicrobial therapy. METHODS: This was a case-control study. Sixty-one patients with BLT-guided adaptation of EAT were prospectively included, and then matched with 61 “controls” having similar infection characteristics (community or hospital-acquired, and source of infection), in whom EAT was conventionally adapted to antibiogram results. Endpoints were to compare the proportion of appropriate (primary endpoint) and optimal (secondary endpoint) antimicrobial therapies with each of the two strategies, once microbiological sample culture results were available. RESULTS: Characteristics of patients, infections and EAT at inclusion were similar between groups. Nine early escalations of EAT occurred in the BLT-guided adaptation group, reaching 98% appropriateness vs. 77% in the conventional adaptation group (p < 0.01). The BLT reduced the time until escalation of an inappropriate EAT from 50.5 (48–73) to 27 (24–28) hours (p < 0.01). Seventeen early de-escalations occurred in the BLT-guided adaptation group, compared to one in the conventional adaptation group, reducing patients’ exposure to broad-spectrum beta-lactam such as carbapenems. In multivariate analysis, use of the BLT was strongly associated with early appropriate (OR = 18 (3.4–333.8), p = 0.006) and optimal (OR = 35.5 (9.6–231.9), p < 0.001) antimicrobial therapies. Safety parameters were similar between groups. CONCLUSIONS: Our study suggests that a BLT-guided adaptation strategy may allow early beta-lactam adaptation from the first 24 hours following the beginning of sepsis management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1746-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5488410
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54884102017-06-30 Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study Garnier, Marc Rozencwajg, Sacha Pham, Tài Vimont, Sophie Blayau, Clarisse Hafiani, Mehdi Fulgencio, Jean-Pierre Bonnet, Francis Mainardi, Jean-Luc Arlet, Guillaume Fartoukh, Muriel Gallah, Salah Quesnel, Christophe Crit Care Research BACKGROUND: Rapid diagnostic tests detecting microbial resistance are needed for limiting the duration of inappropriateness of empirical antimicrobial therapy (EAT) in intensive care unit patients, besides reducing the use of broad-spectrum antibiotics. We hypothesized that the betaLACTA® test (BLT) could lead to early increase in the adequacy of antimicrobial therapy. METHODS: This was a case-control study. Sixty-one patients with BLT-guided adaptation of EAT were prospectively included, and then matched with 61 “controls” having similar infection characteristics (community or hospital-acquired, and source of infection), in whom EAT was conventionally adapted to antibiogram results. Endpoints were to compare the proportion of appropriate (primary endpoint) and optimal (secondary endpoint) antimicrobial therapies with each of the two strategies, once microbiological sample culture results were available. RESULTS: Characteristics of patients, infections and EAT at inclusion were similar between groups. Nine early escalations of EAT occurred in the BLT-guided adaptation group, reaching 98% appropriateness vs. 77% in the conventional adaptation group (p < 0.01). The BLT reduced the time until escalation of an inappropriate EAT from 50.5 (48–73) to 27 (24–28) hours (p < 0.01). Seventeen early de-escalations occurred in the BLT-guided adaptation group, compared to one in the conventional adaptation group, reducing patients’ exposure to broad-spectrum beta-lactam such as carbapenems. In multivariate analysis, use of the BLT was strongly associated with early appropriate (OR = 18 (3.4–333.8), p = 0.006) and optimal (OR = 35.5 (9.6–231.9), p < 0.001) antimicrobial therapies. Safety parameters were similar between groups. CONCLUSIONS: Our study suggests that a BLT-guided adaptation strategy may allow early beta-lactam adaptation from the first 24 hours following the beginning of sepsis management. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1746-6) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-28 /pmc/articles/PMC5488410/ /pubmed/28655352 http://dx.doi.org/10.1186/s13054-017-1746-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Garnier, Marc
Rozencwajg, Sacha
Pham, Tài
Vimont, Sophie
Blayau, Clarisse
Hafiani, Mehdi
Fulgencio, Jean-Pierre
Bonnet, Francis
Mainardi, Jean-Luc
Arlet, Guillaume
Fartoukh, Muriel
Gallah, Salah
Quesnel, Christophe
Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study
title Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study
title_full Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study
title_fullStr Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study
title_full_unstemmed Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study
title_short Evaluation of early antimicrobial therapy adaptation guided by the BetaLACTA® test: a case-control study
title_sort evaluation of early antimicrobial therapy adaptation guided by the betalacta® test: a case-control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488410/
https://www.ncbi.nlm.nih.gov/pubmed/28655352
http://dx.doi.org/10.1186/s13054-017-1746-6
work_keys_str_mv AT garniermarc evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT rozencwajgsacha evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT phamtai evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT vimontsophie evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT blayauclarisse evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT hafianimehdi evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT fulgenciojeanpierre evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT bonnetfrancis evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT mainardijeanluc evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT arletguillaume evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT fartoukhmuriel evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT gallahsalah evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy
AT quesnelchristophe evaluationofearlyantimicrobialtherapyadaptationguidedbythebetalactatestacasecontrolstudy